Follicle‐stimulating hormone promotes growth of human prostate cancer cell line‐derived tumor xenografts-Reference-Cited by-同舟云学术

Follicle‐stimulating hormone promotes growth of human prostate cancer cell line‐derived tumor xenografts

Published:2021-03-16 Issue:4 Volume:35 Page:
ISSN:0892-6638
Container-title:The FASEB Journal
language:en
Short-container-title:FASEB j.

Author:

Oduwole Olayiwola O.¹^ORCID,Poliandri Ariel²,Okolo Anthony¹,Rawson Phil³,Doroszko Milena⁴,Chrusciel Marcin⁴,Rahman Nafis A.⁴⁵,Serrano de Almeida Gilberto⁶,Bevan Charlotte L.⁶,Koechling Wolfgang⁷,Huhtaniemi Ilpo T.¹⁴

Affiliation:

1. Department of Digestion, Metabolism and Reproduction Institute of Reproductive and Developmental Biology Imperial College London London UK

2. Department of Molecular and Clinical Sciences St. George's University of London London UK

3. Central Biomedical Services Imperial College London London UK

4. Institute of Biomedicine University of Turku Turku Finland

5. Department of Reproduction and Gynecological Endocrinology Medical University of Bialystok Bialystok Poland

6. Imperial Centre for Translational and Experimental Medicine Imperial College London London UK

7. Non‐Clinical Development Ferring Pharmaceuticals A/S Copenhagen Denmark

Publisher

Wiley

Subject

Genetics,Molecular Biology,Biochemistry,Biotechnology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1096/fj.202002168RR

Reference36 articles.

1. EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer

2. GnRH Receptors in Cancer: From Cell Biology to Novel Targeted Therapeutic Strategies

3. Risk of disease flare with LHRH agonist therapy in men with prostate cancer: Myth or fact?

4. Pituitary-Testicular Function of Prostatic Cancer Patients During Treatment with a Gonadotropin-Releasing Hormone Agonist Analog I. Circulating Hormone Levels

5. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lower pretreatment serum testosterone level predicts poor prognosis in the patients with metastatic hormone-sensitive prostate cancer undergoing androgen deprivation therapy;Japanese Journal of Clinical Oncology;2024-01-20

2. Cancer stem cells, signalling pathways and chemopreventive effects of phytochemicals in androgen-regulated cancers;Cancer Stem Cells and Signaling Pathways;2024

3. European Society of Toxicologic Pathology (Pathology 2.0 Molecular Pathology Special Interest Group): Review of In Situ Hybridization Techniques for Drug Research and Development;Toxicologic Pathology;2023-04

4. Construction of a Humanized PBMC-PDX Model to Study the Efficacy of a Bacterial Marker in Lung Cancer Immunotherapy;Disease Markers;2022-08-28

5. Effect of Degarelix Administration on Bone Health in Prostate Cancer Patients Without Bone Metastases. The Blade Study;The Journal of Clinical Endocrinology & Metabolism;2022-08-16